Calcipotriene

Calcipotriene

SCHEMBL2854

C=C1/C(=C\C=C2\CCC[C@]3(C)[C@@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@H](O)C[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

VDR

The experimentally established mechanism targets of Calcipotriene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR known ✓ P11473 13/20 1.00
ADORA3 P0DMS8 3/20 1.00
SLC6A2 P23975 3/20 1.00
NR1I2 O75469 2/20 1.00
PGR P06401 2/20 1.00
SLC6A4 P31645 2/20 1.00
ADRA1A P35348 2/20 1.00
PTGS2 P35354 2/20 1.00
HTR1A P08908 1/20 1.00
AGTR1 P30556 2/20 0.67
CYP24A1 Q07973 2/20 0.65
MAPT P10636 2/20 0.64
ABCB11 O95342 1/20 0.64
GC P02774 1/20 0.64
RXRA P19793 1/20 0.64
CHRM3 P20309 1/20 0.64
CNR1 P21554 1/20 0.64
HTR2C P28335 1/20 0.64
MAPK1 P28482 1/20 0.64
OPRD1 P41143 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Calcipotriene SCHEMBL3278756 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL12311926 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL21849105 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL13044528 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL24066882 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL2455296 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL23339038 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL22364326 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL22364325 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR
Calcipotriene SCHEMBL22364327 1.00 VDR (1.00) VDRADORA3SLC6A2NR1I2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 8209 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636262-B2 Process for the preparation of topical formulation Neuheit Pharma Technologies Pvt. Ltd. (IN) 2026-05-26 US claimed
US-12616749-B2 Methods for treatment of psoriasis with an anti-oxLDL antibody ABCENTRA, LLC (US) 2026-05-05 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
WO-2026042066-A1 COMPOUNDS, COMPOSITIONS, AND USE THEREOF FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE DISEASES I DERM PHARMA LTD. (IL) 2026-02-26 WO claimed
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS INC (US) 2026-02-05 US claimed
EP-4647069-A1 DRUGS AND COMPOSITIONS FOR USE IN THE TREATMENT OF RETT SYNDROME UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) 2025-11-12 EP claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
US-20250221982-A1 COMPOSITIONS AND METHODS FOR LOCAL DELIVERY OF PHARMACEUTICAL AGENTS TO TREAT CANCER THE GENERAL HOSPITAL CORPORATION 2025-07-10 US claimed
WO-2025137247-A1 TOPICAL COMPOSITIONS OF GLP-1 AGONISTS AND USE OF GLP-1 AGONISTS AND COMPOSITIONS THEREOF IN TREATING VITILIGO MILGRAUM SANDY S (US) 2025-06-26 WO claimed
WO-2025129271-A1 LIPID DELIVERY VEHICLE THE UNIVERSITY OF QUEENSLAND (AU) 2025-06-26 WO claimed
EP-1067897-A1 AN ACIDIFIED COMPOSITION FOR TOPICAL TREATMENT OF NAIL AND SKIN CONDITIONS Johnson & Johnson Consumer Companies, Inc. (US) 2001-01-17 EP claimed
WO-2001001932-A2 OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE YU RUEY J (US) 2001-01-11 WO claimed
WO-2000070949-A1 METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES HENG MADALENE C Y (US) 2000-11-30 WO claimed
WO-2000057845-A1 METHOD FOR REMOVAL OF HUMAN HORNY TISSUES JOHNSON AND JOHNSON CONSUMER COMPANIES, INC. (US) 2000-10-05 WO claimed
US-6087385-A AN ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS FOR THE TREATMENT OF CERTAIN ENDOCRINE DISEASES LIKE DIABETES, PROSTATE CANCER, BREAST CANCER, PSORIASIS, ACNE, CERTAIN CARDIOVASCULAR DISORDERS INCLUDING HYPERTENSION UNIVERSITY OF MISSISSIPPI (US) 2000-07-11 US claimed
US-6028088-A USEFUL AS ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS; FOR TREATMENT OF CERTAIN ENDOCRINE DISEASES INCLUDING DIABETES, CERTAIN MALIGNANT AND NON-MALIGNANT PROLIFERATIVE DISEASES INCLUDING PROSTATE CANCER THE UNIVERSITY OF MISSISSIPPI (US) 2000-02-22 US claimed
WO-1999049835-A1 AN ACIDIFIED COMPOSITION FOR TOPICAL TREATMENT OF NAIL AND SKIN CONDITIONS JOHNSON AND JOHNSON CONSUMER COMPANIES, INC. (US) 1999-10-07 WO claimed
US-5824313-A ADMINISTERING SPECIFIC ANTIGEN AND LYMPHOID ORGAN MODIFYING AGENT SELECTED FROM CALCIPOTRIENE AND 1,25-DIHYDROXY-16-ENE VITAMIN D3; IMMUNE RESONSE AGAINST HEPATITIS, FLU, DIPHTHERIA, TETANUS, PERTUSSIS, MEASLES, MUMPS, RUBELLA, POLIO, PNEUMONIA, UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 1998-10-20 US claimed
WO-1998020866-A2 METHOD OF TREATING KAPOSI'S SARCOMA BY VITAMIN-D3 RECEPTOR AGONISTS GILL PARKASH S (US) 1998-05-22 WO claimed
WO-1996014048-A1 TREATMENT OF KERATINIC AND PSORIATIC DISORDERS WITH A NAIL LACQUER CONTAINING A VITAMIN D METABOLITE OR DERIVATIVE AND/OR A VITAMIN A DERIVATIVE SEIDENSCHNUR EDEL K (DK) 1996-05-17 WO claimed